Dublin, Jan. 19, 2018 -- The "50 Key Biopharmaceutical and Biotechnology Companies" report has been added to ResearchAndMarkets.com's offering.
50 Key Biopharmaceutical and Biotechnology Companies is a comprehensive look at the top 50 companies that are shaping the biotherapeutics market in 2017 and beyond. The top 50 companies in this report were chosen for a variety of reasons, including sales of marketed biopharmaceutical products, innovation in biotherapeutics, and unique additions to the market, either marketed products or products in development.
50 Key Biopharmaceutical and Biotechnology Companies includes large traditional pharma powerhouses such as Pfizer, Novartis, Roche, Merck, GSK, Bristol-Myers Squibb, Bayer, and others; but it also includes smaller niche companies such as Genmab, Seattle Genetics, etc. In addition, it includes leading biopharmaceuticals such as Amgen and Biogen, and leading biotech companies such as Qiagen, Alexion, Agilent, Waters Co and others.
Biopharmaceuticals are therapeutic agents intended to treat symptoms and/or underlying causes of a variety of disorders and diseases. They have been a growing part of the pharmaceutical landscape since the early 1980s and is, today, one of the fastest growing areas in the pharmaceutical industry, growing at an average rate of 12%-15% over the past two years.
Today, there are many biologics in the approval pipeline and it has been projected that over 65% of drugs approved for the marketplace in 2017 will be the result of biotechnology. Biopharmaceuticals hold great promise for treating some of the most intractable medical conditions such as cancer and autoimmune disease.
50 Key Biopharmaceutical and Biotechnology Companies profiles these market leaders in-depth, presenting detailed information about each company, including:
- Corporate Summary
- Selected Biopharmaceutical Products
- Biopharmaceuticals in Development
- Selected Corporate Developments
- Company Financials
- Regional Revenue Breakdown by Percentage (%)
Key Topics Covered:
1: Executive Summary
Introduction
Scope and Methodology
Market Summary
2: Introduction
Biopharmaceuticals and Biotherapeutics
Biopharmaceuticals
Biotechnology
Areas Of Treatment For Biopharmaceuticals
Regulations For Biopharmaceuticals
3: 50 Key Biopharmaceutical and Biotechnology Companies: Profiles
- AbbVie
- Agilent Technologies Inc.
- Alexion Pharmaceuticals Inc
- Allergan plc
- Ambry Genetics
- Amgen, Inc
- AstraZeneca plc
- Bayer AG
- Berry Genomics Co Ltd.
- Biogen
- BioMarin Pharmaceutical Inc
- Bristol Myers Squibb
- Celgene
- CRISPR Therapeutics AG
- CSL Behring
- Dr. Reddy's Laboratories Limited
- Eli Lilly & Co
- Enzo Biochem, Inc
- Evotec AG
- Exelixis
- Genmab
- Gilead Sciences
- GlaxoSmithKline
- Grifols International S.A.
- Guardant Health
- Illumina
- Incyte Corporation
- Johnson & Johnson
- Merck & Co, Inc.
- Mylan
- Myriad Genetics
- Novartis International AG
- Novo Nordisk A/S
- Organogenesis
- Oxford Nanopore Technologies
- Perkin Elmer, Inc
- Pfizer
- Precision BioSciences Inc
- QIAGEN N.V.
- Regeneron Pharmaceuticals
- Roche Ltd.
- Sanofi
- Seattle Genetics, Inc
- Shire
- Takeda
- Teva Pharmaceutical Industries, Ltd.
- Thermo Fisher Scientific, Inc
- UCB S.A.
- United Therapeutics Corporation
- Waters Corporation
For more information about this report visit https://www.researchandmarkets.com/research/8dx3st/50_key?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biopharmaceuticals


Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Anta Sports Expands Global Footprint With Strategic Puma Stake
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 



